Prescribing DOACs with specific patient populations in mind

Area of Science:

• Clinical Pharmacology
• Internal Medicine
• Pharmacotherapy

Background:

• Obesity, renal disease, cancer, and thrombophilia are prevalent conditions that significantly impact drug pharmacokinetics and pharmacodynamics.
• These comorbidities necessitate individualized prescribing approaches to ensure therapeutic efficacy and minimize adverse events.
• Lack of specific guidance for these patient groups can lead to suboptimal treatment outcomes.

Purpose of the Study:

• To outline key prescribing considerations for patients with obesity, renal disease, cancer, or thrombophilia.
• To highlight potential drug interactions and dosage adjustments required in these complex patient profiles.
• To provide a framework for optimizing pharmacotherapy in vulnerable populations.

Main Methods:

• Review of current literature and clinical guidelines.
• Analysis of pharmacokinetic and pharmacodynamic alterations associated with each comorbidity.
• Synthesis of evidence-based recommendations for drug selection and dosing.

Main Results:

• Specific drug classes require dose modification in renal impairment.
• Obesity can alter drug distribution and metabolism, necessitating weight-based dosing adjustments.
• Cancer patients may experience altered drug clearance and increased risk of toxicity.
• Thrombophilia influences the choice of anticoagulants and requires careful monitoring.

Conclusions:

• Individualized prescribing is essential for patients with obesity, renal disease, cancer, or thrombophilia.
• Healthcare providers must be aware of the unique challenges posed by these comorbidities.
• Adherence to evidence-based guidelines can improve patient safety and treatment effectiveness.